Key facts
- It has raised $50.4M; the latest was Later Stage VC ($25.0M) in Feb 2025.
- Notable investors include University of Toronto, University of Toronto Entrepreneurship, Johnson & Johnson Innovation - JLABS, Perceptive Advisors, Breakthrough T1D — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Zucara
- ·The full record, as it builds
Funding rounds
No funding rounds for Zucara are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zucara
Developer of a novel drug therapy designed to prevent hypoglycemia in people with diabetes. The company's drug therapy is delivered as a subcutaneous injection, which will benefit patients by addressing the significant morbidity and mortality associated with hypoglycemia, enabling healthcare providers to change diabetes disease management and improve patient health.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2015
- Employees
- 12
- Website
- zucara.ca/
- Ownership
- Privately Held (backing)
Zucara doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zucara shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zucara in its N-PORT filings yet. We sweep new filings monthly.